Elevai Labs Inc

Earnings data Q3 2024

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevai Labs, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed and Jordan R. Plews in 2020 and is headquartered in Newport Beach, CA.

Elevai Labs (NASDAQ: ELAB ) just reported results for the third quarter of 2024. Elevai Labs reported earnings per share of -7.8 cents.

ELAB Stock Earnings: Elevai Labs Reported Results for Q3 2024

NEWPORT BEACH, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for its Q3 2023 fiscal quarter, ended September 30, 2023.

Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023

NEWPORT BEACH, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with Skin Sana Ltd.

ELEVAI Labs, Inc. Expands International Distribution into Europe

NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience's mitochondrial research with ELEVAI's PREx™ (Precision Regenerative Exosome Technology™) to potentially develop topical skincare formulations that combine mitochondrial biology with Elevai's human umbilical mesenchymal stem cell derived exosomes.

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

Smith Douglas Homes Corp

Waystar Holding Corp

ZEEKR Intelligent Technology Holding Ltd

Skincare company Elevai Labs priced at the low end to raise $6 million at a $69 million market cap. Colombier Acquisition Corp. II upsized to raise $150 million. Several issuers are primed for post-Thanksgiving launches.

U.S. IPO Weekly Recap: IPO Market Sees A Little Activity In The Short Holiday Week

Elevai Labs, Inc. plans to raise $7.5 million in an IPO of its common stock. The company develops and sells topical aesthetic skincare products. Due to management's excessive valuation assumptions, little revenue, and growing losses, my outlook on the IPO is bearish [Sell].

Elevai Labs Seeks Micro-IPO Despite Little Revenue

News for Elevai Labs Inc Stock (ELAB)